Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalFRA:SD4 +0.63%18 Receivables Turnover is 1.36 as of Jun. 2026. GuruFocus rates FRA:SD4 with a GF Score™ of 18/100 and a GF Value™ of €0.50 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Spectral Medical ranks better than 67.33% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Spectral Medical's Revenue for the
three
months ended in Jun. 2026 was €0.38 Mil. Spectral Medical's average Accounts Receivable for the
three
months ended in Jun. 2026 was €0.28 Mil.
Hence, Spectral Medical's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.36.
Spectral Medical (FRA:SD4) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Spectral Medical Receivables Turnover Related Terms
Spectral Medical Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:SD4 vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Spectral Medical's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Spectral Medical's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (FRA:SD4) has a Receivables Turnover of 1.36 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Spectral Medical and its competitors. According to the industry distribution chart, Spectral Medical ranks #66 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 32.7%.
Is Spectral Medical's Receivables Turnover too high?
Spectral Medical's current Receivables Turnover is 1.36. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Spectral Medical's value of 1.36 is 74.7% below this industry median. Based on the distribution chart, Spectral Medical ranks #66 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Spectral Medical has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #66 out of 202 companies for Receivables Turnover. This puts Spectral Medical in the upper half of its industry. The industry median Receivables Turnover is 5.38. Spectral Medical's value of 1.36 is 74.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spectral Medical's current Receivables Turnover of 1.36 is 74.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Receivables Turnover is 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (FRA:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.50, compared to a current price of €0.80 — trading 59% above its estimated fair value. The current Receivables Turnover is 1.36 and 74.7% below the Medical Diagnostics & Research industry median of 5.38. Spectral Medical's overall GF Score™ is 18/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Spectral Medical (FRA:SD4), the current Receivables Turnover is 1.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (FRA:SD4) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of €0.80 is trading 59% above its estimated GF Value™ of €0.50.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for FRA:SD4:
Receivables Turnover: 1.36
GF Value™: €0.50 vs. price of €0.80 (59% above fair value)
Industry Position: 74.7% below the Medical Diagnostics & Research median (#66 of 202)
No single metric tells the full story. See the FRA:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
18GF Score
Get the complete analysis for FRA:SD4
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SD4 has been successfully added to your 
